Oral Spray Vaccine 54% More Effective Than Antibiotics for UTIs

Oral Spray Vaccine 54% More Effective Than Antibiotics for UTIs
Oral Spray Vaccine 54% More Effective Than Antibiotics for UTIs. Credit | Getty images

United States: The most recent breakthrough is that a new vaccine has been put to the test in people with recurring urinary tract infections (UTI), and it was concluded that the best option is the vaccine instead of antibiotics.

More than 50 percent (54%) of those with recurring UTIs remained free from infection nine years after receiving the oral spray vaccine, along with no apparent side effects of its own, as the findings of the study showed.

Bob Yang, a co-lead researcher and a consulting urologist at the Royal Berkshire NHS Foundation Trust in the U.K., said, “Before having the vaccine, all our participants suffered from recurrent UTIs, and for many women, these can be difficult to treat,” as US News reported.

Moreover, “Nine years after first receiving this new UTI vaccine, around half of the participants remained infection-free,” and “Overall, this vaccine is safe in the long term, and our participants reported having fewer UTIs that were less severe. Many of those who did get a UTI told us that simply drinking plenty of water was enough to treat it,” Yang continued.

More about vaccine

It was developed by researchers at the Spanish pharmaceutical company Immunotek. It is called the MV140 vaccine, which consisted of four bacterial species added inside a pineapple-flavored suspension of water, as the reports said.

By administering a dose of the vaccine, the bacteria contained induce the body to make antibodies capable of fighting infection.

The way of administering the vaccine is through two spritzes placed under the tongue and given every day for three months.

According to US News reports, UTIs are considered the most commonly found bacteria-related infection. It is found in almost half of the women and one in five men.

The number of recurring infection cases that needed antibiotics formed in 20 percent to 30 percent of cases.

About the trial

For the purpose of the study, 72 women and 17 men who were receiving treatment at Royal Berkshire Hospital in the UK for urinary tract infections participated. Moreover, these patients have been involved in an original clinical trial for MV140, which has been further followed for almost a year.

Next, the recent nine-year follow-up study led the researchers to examine the resulting outcomes from the total of 89 participants and further questioned for better analysis.

Dr. Gernot Bonkat, a professor at the Alta Uro Medical Centre for Urology in Switzerland, said, “These findings are promising. Recurrent UTIs are a substantial economic burden, and the overuse of antibiotic treatments can lead to antibiotic-resistant infections,” as the US News reports.

Bonkat added, “Further research into more complex UTIs is needed, as well as research looking at different groups of patients, so we can better optimize how to use this vaccine,” and, “While we need to be pragmatic, this vaccine is a potential breakthrough in preventing UTIs and could offer a safe and effective alternative to conventional treatments.”